Huimu Shines at VIV Asia 2025, Leading New Trends in Asian Livestock Industry

From March 12 to 14, 2025, the spotlight of Asia's livestock industry converged at the IMPACT Exhibition Center in Bangkok, Thailand, as VIV Asia 2025—one of the region's largest livestock exhibitions—successfully concluded. Serving as a vital bridge connecting domestic and international livestock markets, this expo provided an exceptional platform for industry exchange and collaboration.

Huimu, a company dedicated to the R&D, raw material production, formulation, and global marketing of two major products—Halofuginone for coccidiosis control and Yeast Polysaccharides—made a strong appearance at the event. Led by Tan Yingwen, the company’s leadership, along with its international trade team, engaged with both new and existing partners to explore innovative approaches, share the latest advancements, and elevate collaborative success to new heights.

At VIV Asia 2025, Huimu showcased its latest R&D achievements in animal health to global visitors, including:

• The highly effective, residue-free novel anticoccidial drug - Halofuginone

• Hydrolyzed Yeast Polysaccharides extracted through proprietary enzymatic technology

These products have not only been widely applied in many countries and regions but have also gained high recognition in international markets for their outstanding performance and innovation.

Halofuginone, as a new type of anticoccidial drug, has a unique chemical structure that prevents cross-resistance with other coccidiostats. It shows high sensitivity against all Eimeria species infecting chickens. Additionally, Halofuginone has no side effects on chickens, does not affect their immunity development against coccidia or kidney function, and is compatible with any feed additives or therapeutic drugs. After three years of market promotion, Huimu's Halofuginone formulation has demonstrated high efficacy in coccidiosis control in multiple countries and regions, presenting the perfect solution for coccidiosis prevention and control.

Hydrolyzed Yeast Polysaccharides are natural compounds extracted from yeast cell walls through high-temperature enzymatic technology, with the main active components being β-1,3/1,6-D-glucan and Mannan Oligosaccharides (MOS). They offer multiple benefits including immune regulation, harmful bacteria elimination, mycotoxin adsorption, antioxidant and anti-stress effects, and improved vaccine efficacy, thereby significantly enhancing animal growth performance and health. It serves as an ideal antibiotic alternative. In clinical applications, the company's high-content MOS and β-1,3/1,6-D-glucan monomers exhibit excellent water solubility, facilitating administration through drinking water and expanding product application scenarios.

Nantong Yinqi, as Huimu's strategic partner, is a professional manufacturer of yeast and yeast-derived products. The company possesses advanced yeast processing production lines with an annual output exceeding 30,000 tons, offering product series including yeast extracts, yeast cell walls, and live yeast. Its products provide significant advantages in livestock farming, such as improving feed palatability, promoting animal growth, and enhancing immunity, delivering green and efficient solutions for the industry.

Looking ahead, Huimu will continue its international journey. As an emerging enterprise in the livestock industry, Huimu remains committed to innovation-driven development and winning markets through quality. In the future, the company will continue to refine its expertise, promote the globalization of China's livestock industry, and contribute Chinese wisdom and strength to the sustainable development of the global livestock sector.